| 48.3 -0.91 (-1.85%) | 12-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 59.78 | 1-year : | 69.83 |
| Resists | First : | 51.18 | Second : | 59.78 |
| Pivot price | 41.52  |
|||
| Supports | First : | 36.35 |
Second : | 27.19 |
| MAs | MA(5) : | 47.51 |
MA(20) : | 38.29 |
| MA(100) : | 28.16 |
MA(250) : | 0 | |
| MACD | MACD : | 5.1 |
Signal : | 4.1 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 93 |
| RSI | RSI(14): 77.5 |
|||
| 52-week | High : | 51.18 | Low : | 18.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VERA ] has closed below upper band by 23.2%. Bollinger Bands are 254.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 29 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.79 - 50.13 | 50.13 - 50.4 |
| Low: | 47.3 - 47.62 | 47.62 - 47.89 |
| Close: | 47.83 - 48.35 | 48.35 - 48.78 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Tue, 16 Dec 2025
Latham & Watkins Represents Vera Therapeutics in US$300 Million Offering of Common Stock - Legal Desire Media and Insights
Tue, 16 Dec 2025
Hudson Bay Capital Management LP Acquires Shares of 298,976 Vera Therapeutics, Inc. $VERA - MarketBeat
Tue, 16 Dec 2025
Vera Therapeutics announces $200M public offering - MSN
Mon, 15 Dec 2025
Patrick Enright Acquires 5,882 Shares of Vera Therapeutics (NASDAQ:VERA) Stock - MarketBeat
Sat, 13 Dec 2025
Vera Therapeutics Sees Optimism as Analysts Boost Price Targets - timothysykes.com
Thu, 11 Dec 2025
Wedbush Maintains Vera Therapeutics (VERA) Neutral Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 10,820 (K) |
| Shares Short P.Month | 9,260 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -73.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -127 (M) |
| PE Ratio | -12.11 |
| PEG Ratio | 0 |
| Price to Book value | 7.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|